A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Официальное название

A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Обзор

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before. The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug in combination with lenalidomide * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality-of-life and ability to complete routine daily activities

Вмешательства

• Препарат Odronextamab
  Administered per the protocol
• Препарат Lenalidomide
  Administered per the protocol
• Препарат Rituximab
  Administered per the protocol

Первичные конечные точки

• Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide [Срок оценки: Up to 35 days]
• Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomide [Срок оценки: Up to 2 years]
• Severity of TEAEs for odronextamab in combination with lenalidomide [Срок оценки: Up to 2 years]
• Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR) in participants with R/R FL and participants with indolent lymphoma [Срок оценки: Up to 5 years]

Вторичные конечные точки (12)

• Odronextamab concentrations in serum [Срок оценки: Up to 30 months]
• Incidence of Anti-drug Antibodies (ADA) to odronextamab [Срок оценки: Up to 30 months]
• Magnitude of ADAs to odronextamab [Срок оценки: Up to 30 months]
• Best Overall Response (BOR) as assessed by investigator review [Срок оценки: Up to 30 months]
• Duration of Response (DOR) as assessed by investigator review [Срок оценки: Up to 5 years]
• PFS as assessed by investigator review [Срок оценки: Up to 5 years]
• Complete Response (CR) as assessed by ICR [Срок оценки: Up to 30 months]
• BOR as assessed by ICR [Срок оценки: Up to 30 months]
• Overall Survival (OS) [Срок оценки: Up to 5 years]
• Event Free Survival (EFS) as assessed by ICR [Срок оценки: Up to 5 years]
• EFS as assessed by local investigator review [Срок оценки: Up to 5 years]
• DOR as assessed by ICR [Срок оценки: Up to 5 years]

Критерии участия

Критерии включения

• Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol.
• Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody and participant should meet indication for treatment, as described in the protocol.
• Have measurable disease on cross sectional imaging documented by diagnostic Computed Tomography \[CT\], or Magnetic Resonance Imaging \[MRI\] imaging, as described in the protocol.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• Adequate hematologic and organ function, as described in the protocol.
• All study participants must:

• Have an understanding that lenalidomide could have a potential teratogenic risk.
• Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide.
• Agree not to share study medication with another person.
• Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide.

Критерии исключения

• Primary Central Nervous System (CNS) lymphoma or known involvement (either current or prior history of CNS involvement) by non-primary CNS NHL, as described in the protocol.
• Participants with current or past histological evidence of high-grade or diffuse large B-cell lymphoma, or any histology other than FL grade 1-3a or MZL.
• History of or current relevant CNS pathology, as described in the protocol.
• A malignancy other than NHL (inclusion diagnosis) unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated.
• Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
• Allergy/hypersensitivity to study drugs or excipients. as described in the protocol.
• Active infection as defined in the protocol.

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Италия · 18 центров

• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori — Meldola
• Ospedale Policlinico San Martino IRCCS — Genoa
• S Gerardo Hospital — Monza
• A.O.U. Citta della Salute e della Scienza di Torino — Turin
• Centro Di Riferimento Oncologico (CRO), Aviano, National Cancer Institute — Aviano
• Candiolo Cancer Institute, FPO, IRCCS — Candiolo
• University of Bologna Dipartimento di Medicina Specialistica Diagnostica e Sperimentale — Bologna
• Azienda Ospedaliera Spedali Civili di Brescia — Brescia
• … и ещё 10 центров

Испания · 18 центров

Список центров уточняется — проверьте первичный протокол.

Франция · 17 центров

• Institut Paoli-Calmettes — Marseille
• CHU de Rennes — Rennes
• Centre Hospitalier Regional Universitaire de Tours — Tours
• Polyclinique Bordeaux Nord Aquitaine — Bordeaux
• Centre Francois Magendie — Pessac
• Hopital Saint Vincent-de-Paul — Lille
• Centre Henri Becquerel — Rouen
• Nantes University Hospital — Nantes
• … и ещё 9 центров

South Korea · 13 центров

Список центров уточняется — проверьте первичный протокол.

Тайвань · 12 центров

Список центров уточняется — проверьте первичный протокол.

Польша · 11 центров

Список центров уточняется — проверьте первичный протокол.

Turkey (Türkiye) · 11 центров

Список центров уточняется — проверьте первичный протокол.

Бразилия · 10 центров

• Hospital Sao Rafael — Salvador
• Hospital Sirio Libanes Brasilia — Brasília
• Uopeccan Hospital do Cancer de Cascavel — Cascavel
• Hospital Erasto Gaertner — Curitiba
• Hospital de Clinicas de Porto Alegre — Porto Alegre
• Centro Gaucho Integrado — Porto Alegre
• Amaral Carvalho Hospital — Jaú
• Instituto Nacional de Cancer Jose Alencar Gomes da Silva — Rio de Janeiro
• … и ещё 2 центра

Германия · 9 центров

• Stauferklinikum — Mutlangen
• Robert-Bosch-Krankenhaus — Stuttgart
• LMU Klinikum — Munich
• TUM Fakultat fur Medizin - Klinikum Rechts der Isar — Munich
• Clinic Frankfurt (Oder) — Frankfurt am Main
• Universitatsmedizin der Johannes-Gutenberg Universitat Mainz — Mainz
• University Hospital Halle Saale — Halle
• Stadtisches Krankenhaus Kiel — Kiel
• … и ещё 1 центр

Великобритания · 9 центров

Список центров уточняется — проверьте первичный протокол.

США · 8 центров

• David Geffen School of Medicine at UCLA — Los Angeles
• Boca Raton Clinical Research (BRCR) Global — Plantation
• Indiana University and Comprehensive Cancer Center — Indianapolis
• Hattiesburg Clinic — Hattiesburg
• Dartmouth Cancer Center — Lebanon
• Stony Brook University Hospital — Stony Brook
• Clinical Research Alliance Inc — Westbury
• Prohealth Care Inc — Waukesha

Израиль · 7 центров

• Assuta Ashdod Medical Center — Ashdod
• Hadassah Medical Center — Jerusalem
• Galilee Medical Center — Nahariya
• Rabin Medical Center — Petah Tikva
• Chaim Sheba Medical Center — Ramat Gan
• The Tel Aviv Sourasky Medical Center — Tel Aviv
• Assuta Medical Centers — Tel Aviv

Австралия · 5 центров

• Liverpool Hospital — Liverpool
• Calvary Mater Newcastle — Waratah
• Pindara Private Hospital — Benowa
• Royal Hobart Hospital — Hobart
• Epworth Freemasons — East Melbourne

Бельгия · 5 центров

• Centre Hospitalier Universitaire at Universite Catholique de Louvain Namur — Yvoir
• Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital — Ghent
• Algemeen Ziekenhuis AZ Delta — Roeselare
• Ziekenhuis Netwerk Antwerpen Stuivenberg — Antwerp
• Institut Jules Bordet — Brussels

Малайзия · 5 центров

Список центров уточняется — проверьте первичный протокол.

Австрия · 4 центра

• Ordensklinikum Linz — Linz
• Kepler University Hospital — Linz
• Medical University Vienna — Vienna
• Klinikum Wels-Grieskirchen — Wels

Чехия · 4 центра

• University Hospital Hradec Kralove — Hradec Králové
• Fakultni Nemocnice Brno — Brno
• University Hospital Kralovske Vinohrady — Prague
• Vseobecna Fakultni Nemocnice V Praze — Prague

Таиланд · 3 центра

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT06149286 · R1979-ONC-22102 · 2022-503092-28-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗